dras knowledge

Friday, August 05, 2005

Implanted Brain Stimulators for Depression

http://www.usatoday.com/news/health/2005-07-17-brain-depression_x.htm

Stimulating the brain via some external electrical device for the treatment of depression has been advocated (at least commercially) since the mid-80's. No device has yet been FDA approved.

The Cyberonics device mentioned in the USA today article is IMPLANTED in your brain. Ick. You should have some serious, intractible, suicidal depression before ever considering such a thing. But, it does have FDA approval.

Remember, FDA CDRH approvals, even PMA approvals, are more concerned with safety, and demonstration that the device conforms to its labeling, rather than much determination as to whether or not it actually achieves a therapeutic purpose. Apparently, following initial FDA approval last year, CDRH asked the manufacturer for additional statistical analysis within their clinical study. This has been submitted and in July 2005, the FDA updated the labeling and summary of Safety and Effectiveness documents.

Here's what the FDA looked at in it's approval:



The overall FDA summary is positive in the device's ability to effect outcomes in the labeled populations. Labeling is one key here, the indicated population truly is sincerely desparate.

Other keys. The FDA looked at only one, on-going study, sponsored by the manufacturer. A manufacturer who is trying to woo investors, see a return on research investment, and otherwise has every stake in the product's success. The design and presentation of the study to the FDA left much to be desired. It wasn't a very ideal study. The conclusions of the CDRH analysis of the additional requested study-related data about the active (D-04) and control (D-02) groups reads, in part:

"Due to above statistical issues, such as questionable concordance between HRSD- 24 and IDS-SR, questionable pooling of multi-center data for comparison of proportions of responses, statistically insignificant findings from censored and overlapping sites (Tables 8-C and 8-D) for IDS-SR primary effectiveness endpoint (Slope) and HRSD-24 secondary effectiveness endpoint (Response proportions), it is unclear whether the effectiveness claim of D-02 over D-04 group patients has been demonstrated."

My summary, if you go by what the manufacturer says, the implanted brain stimulator can likely help out depression when all other things fail. If you go by a literal analysis of the technology, it realy hasn't been demonstrated that we can predict better outcomes for depression by using implanted brain stimulation, than by not using one. Implanting brain stimulators is risky, and a clear benefit has not been demonstrated practically enough to offset the risks and expense.

It's depressing to think there will probably be plenty of people who will want one, for all kinds of reasons, and enough willing surgeons around to meet the demand. -dras

Brain Stimulator for Depression

http://www.usatoday.com/news/health/2005-07-17-brain-depression_x.htm

Stimulating the brain via some external electrical device for the treatment of depression has been advocated (at least commercially) since the mid-80's. No device has yet been FDA approved.

The Cyberonics device mentioned in the USA today article is IMPLANTED in your brain. Ick. You should have some serious, intractible, suicidal depression before ever considering such a thing. But, it does have FDA approval. Remember, FDA CDRH approvals, even PMA approvals, are more concerned with safety, and demonstration that the device conforms to its labeling, rather than much determination as to whether or not it actually achieves a therapeutic purpose. Apparently, following initial FDA approval last year, CDRH asked the manufacturer for additional statistical analysis within their clinical study. This has been submitted and in July 2005, the FDA updated the labeling and summary of Safety and Effectiveness documents.

Here's what the FDA looked at in it's approval:

http://www.fda.gov/cdrh/PDF/p970003s050b.pdf

http://www.fda.gov/ohrms/dockets/dockets/05m0283/05m-0283-aav0001-02-Approval-Order-vol1.pdf

http://www.fda.gov/ohrms/dockets/dockets/05m0283/05m-0283-aav0001-02-Approval-Order-vol1.pdf

http://www.fda.gov/ohrms/dockets/ac/04/briefing/4047b1_00_a_FDA%20Statistical%20Review%20Memo.pdf

The overall FDA summary is positive in the device's ability to effect outcomes in the labeled populations. Labeling is one key here, the indicated population truly is sincerely desparate. Other keys. The FDA looked at only one, on-going study, sponsored by the manufacturer. A manufacturer who is trying to woo investors, see a return on research investment, and otherwise has every stake in the product's success. The design and presentation of the study to the FDA left much to be desired. It wasn't a very ideal study. The conclusions of the CDRH analysis of the additional requested study-related data about the active (D-04) and control (D-02) groups reads, in part:

"Due to above statistical issues, such as questionable concordance between HRSD- 24 and IDS-SR, questionable pooling of multi-center data for comparison of proportions of responses, statistically insignificant findings from censored and overlapping sites (Tables 8-C and 8-D) for IDS-SR primary effectiveness endpoint (Slope) and HRSD-24 secondary effectiveness endpoint (Response proportions), it is unclear whether the effectiveness claim of D-02 over D-04 group patients has been demonstrated."

My summary, if you go by what the manufacturer says, the implanted brain stimulator can likely help out depression when all other things fail. If you go by a literal analysis of the technology, it realy hasn't been demonstrated that we can predict better outcomes for depression by using implanted brain stimulation, than by not using one. Implanting brain stimulators is risky, and a clear benefit has not been demonstrated practically enough to offset the risks and expense. It's depressing to think there will probably be plenty of people who will want one, for all kinds of reasons, and enough willing surgeons around to meet the demand.

-dras

Tuesday, August 02, 2005

Nitric Oxide and body building

Nitric Oxide (NO) can be commonly known as the exhaust gas that becomes poisonous Nitrogen Dioxide (NO2) For some time, and in limited situations, inhaled NO gas -as a toxic vasodilator- has been used successfully in some very severe lung conditions.

The body's interaction with nitrates is epic. All the particulars of how the human body uses, and is effected by NO at the tissue level are just beginning to be understood. It's easy to see how the supplement industry can implicate NO precursors like L-arginine with post-menopausal symptoms and effects, impotence, headache, healing, exercise ability, disease prevention, and as a metabolic enhancement to steroids among others. Even though you can trace these associations to science, practical application through oral supplementation is not yet demonstrated. BTW, L-arginine is your common "natural" growth hormone supplement, see arginine hydrochloride.

Just in the last several months, newer studies have demonstrated positive effects of L-arginine supplementation for the treatment of hypertensive conditions associated with heart surgeries. Other studies showed potential positive benefit for cystic fibrosis, other heart conditions, and wound healing.

L-arginine is a pretty cheap supplement to produce. It's a naturally occurring amino acid and essentially non-toxic. You probably get all you need from a normal diet of chocolate, nuts, dairy and whole grains (not necessarily in that order.)I don't know much about potential other "sources" of Nitric Oxide as peddled in nutritional supplement land, but the jury is still way out, as far as published science is concerned, on L-arginine having positive impacts for otherwise healthy people, or for body builders in particular.

-dras

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?CMD=PagerDB=pubmed

Lim DS, Mooradian SJ, Goldberg CS, Gomez C, Crowley DC, Rocchini AP, Charpie JR. Effect of oral L-arginine on oxidant stress, endothelial dysfunction, and systemic arterial pressure in young cardiac transplant recipients. Am J Cardiol. 2004 Sep 15;94(6):828-31

Grasemann H, Grasemann C, Kurtz F, Tietze-Schillings G, Vester U, Ratjen F. Oral L-arginine supplementation in cystic fibrosis patients: a placebo-controlled study. Eur Respir J. 2005 Jan;25(1):62-8. PMID: 15640324

Neri I, Blasi I, Facchinetti F. Effects of acute L-arginine infusion on non-stress test in hypertensive pregnant women. J Matern Fetal Neonatal Med. 2004 Jul;16(1):23-6. PMID: 15370078

Rytlewski K, Olszanecki R, Korbut R, Zdebski Z. Effects of prolonged oral supplementation with l-arginine on blood pressure and nitric oxide synthesis in preeclampsia. Eur J Clin Invest. 2005 Jan;35(1):32-7. PMID: 15638817

Bednarz B, Jaxa-Chamiec T, Gebalska J, Herbaczynska-Cedro K, Ceremuzynski L. L-arginine supplementation prolongs exercise capacity in congestive heart failure. Kardiol Pol. 2004 Apr;60(4):348-53. English, Polish. PMID: 15226784

Bednarz B, Jaxa-Chamiec T, Maciejewski P, Szpajer M, Janik K, Gniot J, Kawka-Urbanek T, Drozdowska D, Gessek J, Laskowski H. Efficacy and safety of oral l-arginine in acute myocardial infarction. Results of multicenter, randomized, double-blind, placebo-controlled ARAMI pilot trial. Kardiol Pol. 2005 May;62(5):421-427. PMID: 15928719